4.7 Review

Inflammation and Epilepsy in the Developing Brain: Clinical and Experimental Evidence

Journal

CNS NEUROSCIENCE & THERAPEUTICS
Volume 21, Issue 2, Pages 141-151

Publisher

WILEY
DOI: 10.1111/cns.12371

Keywords

Developing Brain; Epilepsy; Epileptogenesis; IL-1; Inflammation

Funding

  1. INSERM, Universite Paris-Diderot
  2. Association INJENO

Ask authors/readers for more resources

There is an increasing evidence to support a role of inflammatory processes in epilepsy. However, most clinical and experimental studies have been conducted in adult patients or using adult rodents. The pediatric epilepsies constitute a varied group of diseases that are most frequently age specific. In this review, we will focus on the possible role of inflammation in pediatric epilepsy syndromes. We will first describe the clinical data available and provide an overview of our current understanding of the role of inflammation in these clinical situations. We will then review experimental data regarding the role of inflammation in epilepsy in the developing brain. To summarize, inflammation contributes to seizure precipitation, and reciprocally, prolonged seizures induce inflammation. There is also a relationship between inflammation and cell injury following status epilepticus, which differs according to the developmental stage. Finally, inflammation seems to contribute to epileptogenesis even in the developing brain. Based on the available data, we highlight the need for further studies dissecting the exact role of inflammation in epilepsy during development.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Pediatrics

Why monitor the neonatal brain-that is the important question

Sampsa Vanhatalo, Nathan J. Stevenson, Ronit M. Pressler, Nicholas S. Abend, Stephane Auvin, Francesco Brigo, M. Roberta Cilio, Cecil D. Hahn, Hans Hartmann, Lena Hellstrom-Westas, Terrie E. Inder, Solomon L. Moshe, Magda L. Nunes, Renee A. Shellhaas, Kollencheri P. Vinayan, Linda S. de Vries, Jo M. Wilmshurst, Elissa Yozawitz, Geraldine B. Boylan

Summary: Brain monitoring plays a crucial role in neonatal neurocritical care, but recent research failed to prove its effectiveness in seizure treatment.

PEDIATRIC RESEARCH (2023)

Article Behavioral Sciences

Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: A critical period for early neurodevelopment

Kim I. Bishop, Peter K. Isquith, Gerard A. Gioia, Kelly G. Knupp, Ingrid E. Scheffer, Rima Nabbout, Nicola Specchio, Joseph Sullivan, Stephane Auvin, J. Helen Cross, Renzo Guerrini, Gail Farfel, Bradley S. Galer, Arnold R. Gammaitoni

Summary: This study aimed to evaluate the association between fenfluramine (FFA) and improvement in everyday executive function (EF) in preschool-aged children with Dravet syndrome (DS). The results showed that the FFA treatment group demonstrated reliable and clinically meaningful improvement in self-control, flexibility, metacognition, and overall executive function. Among the FFA treatment groups, the 0.7 mg/kg/day dosage group showed the most significant improvement.

EPILEPSY & BEHAVIOR (2023)

Letter Pediatrics

Spontaneously Resolving Encephalitis in Children with Acute COVID Infection

Manon Casabianca, Julia Roux, Stephane Auvin, Luigi Titomanlio, Kumaran Deiva, Lea Lenglart

INDIAN JOURNAL OF PEDIATRICS (2023)

Review Clinical Neurology

Time-to-event clinical trial designs: Existing evidence and remaining concerns

Wesley T. Kerr, Stephane Auvin, Serge Van der Geyten, Christopher Kenney, Gerald Novak, Nathan B. Fountain, Caitlin Grzeskowiak, Jacqueline A. French

Summary: Well-designed placebo-controlled clinical trials are crucial for the development of new epilepsy treatments, but the design has remained unchanged for decades. Concerns have been raised by patients, clinicians, regulators, and innovators about the challenges of recruiting for trials, partly due to the static design of maintaining participants on add-on placebo for long periods of time when there are more therapy options available. Time-to-event trials, although having potential limitations, have been suggested as a promising mechanism to make trials more patient-friendly and reduce placebo exposure.

EPILEPSIA (2023)

Article Clinical Neurology

Seizure-free days as a novel outcome in patients with Lennox-Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trials

Stephane Auvin, Charlotte Nortvedt, Douglas S. Fuller, Farhad Sahebkar

Summary: This post hoc analysis evaluated the use of seizure-free days as a potential outcome measure in randomized placebo-controlled trials for patients with Lennox-Gastaut syndrome (LGS). The results showed that seizure-free days can be a meaningful and new endpoint for future trials in LGS patients.

EPILEPSIA (2023)

Editorial Material Clinical Neurology

Unjustified allegation on cancer risks in children of mothers with epilepsy taking high-dose folic acid during pregnancy-No proof of a causal relationship

Randi von Wrede, Juri-Alexander Witt, Stephane Auvin, Anita Devlin, Lieven Lagae, Anthony Marson, Kimford J. Meador, Terence J. O'Brien, Jun Park, Rainer Surges, Eugen Trinka, Samuel Wiebe, Christoph Helmstaedter

EPILEPSIA (2023)

Article Neurosciences

Plasma lysosphingolipids in GRN-related diseases: Monitoring lysosomal dysfunction to track disease progression

Walid Khrouf, Dario Saracino, Benoit Rucheton, Marion Houot, Fabienne Clot, Daisy Rinaldi, Joana Vitor, Marie Huynh, Evelyne Heng, Dimitri Schlemmer, Florence Pasquier, Vincent Deramecourt, Sophie Auriacombe, Carole Azuar, Richard Levy, Stephanie Bombois, Claire Boutoleau-Bretonniere, Jeremie Pariente, Mira Didic, David Wallon, Frederique Fluchere, Stephane Auvin, Imen Ben Younes, Yann Nadjar, Alexis Brice, Bruno Dubois, Dominique Bonnefont-Rousselot, Isabelle Le Ber, Foudil Lamari

Summary: GRN mutations lead to increased plasma levels of lysosphingolipids (lysoSPL) in individuals with frontotemporal dementia (FTD). Among FTD patients, lysoSPL levels are specifically elevated in GRN carriers. LGL1 levels are associated with neurofilament increases in presymptomatic carriers.

NEUROBIOLOGY OF DISEASE (2023)

Article Clinical Neurology

mTOR-therapy and targeted treatment opportunities in mTOR-related epilepsies associated with cortical malformations

S. Auvin, S. Baulac

Summary: Dysregulation of the mTOR pathway has been well studied in various neurodevelopmental disorders associated with epilepsy. Mutations in mTOR pathway genes play a role in tuberous sclerosis complex and different cortical malformations, leading to the concept of mTORopathies. This suggests that mTOR inhibitors could be used as antiseizure medication.

REVUE NEUROLOGIQUE (2023)

Article Clinical Neurology

Perampanel outcomes at different stages of treatment in people with focal and generalized epilepsy treated in clinical practice: Evidence from the PERMIT study

Claudio Liguori, Estevo Santamarina, Adam Strzelczyk, Juan Jesus Rodriguez-Uranga, Rohit Shankar, Xiana Rodriguez-Osorio, Stephane Auvin, Paolo Bonanni, Eugen Trinka, Rob McMurray, Ricardo Sainz-Fuertes, Vicente Villanueva

Summary: The PERMIT study is the largest analysis of perampanel clinical practice data. The results showed that early add-on therapy with perampanel was more effective and better tolerated compared to late add-on therapy.

FRONTIERS IN NEUROLOGY (2023)

Letter Clinical Neurology

Response: Drug resistance in epilepsy: A reappraisal of the definition is needed

Aristea S. Galanopoulou, Stephane Auvin, Solomon L. Moshe, Heidrun Potschka, Luisa Rocha, Matthew C. Walker

EPILEPSIA (2023)

Article Clinical Neurology

Treatment of seizures in the neonate: Guidelines and consensus-based recommendations-Special report from the ILAE Task Force on Neonatal Seizures

Ronit M. Pressler, Nicholas S. Abend, Stephan Auvin, Geraldine Boylan, Francesco Brigo, Maria Roberta Cilio, Linda S. De Vries, Maurizio Elia, Alberto Espeche, Cecil D. Hahn, Terrie Inder, Nathalie Jette, Angelina Kakooza-Mwesige, Silke Mader, Eli M. Mizrahi, Solomon L. Moshe, Lakshmi Nagarajan, Iris Noyman, Magda L. Nunes, Pauline Samia, Eilon Shany, Renee A. Shellhaas, Ann Subota, Chahnez Charfi Triki, Tammy Tsuchida, Kollencheri Puthenveettil Vinayan, Jo M. Wilmshurst, Elissa G. Yozawitz, Hans Hartmann

Summary: Seizures in neonates are common, and the management of neonatal seizures varies significantly. The Neonatal Task Force of the International League Against Epilepsy has developed evidence-based recommendations for the management of antiseizure medication in neonates. These recommendations cover the choice of first-line and second-line medications, control of seizure burden, the use of therapeutic hypothermia, and other considerations.

EPILEPSIA (2023)

Article Clinical Neurology

Revisiting the concept of drug-resistant epilepsy: A TASK1 report of the ILAE/AES Joint Translational Task Force

Stephane Auvin, Aristea S. Galanopoulou, Solomon L. Moshe, Heidrun Potschka, Luisa Rocha, Matthew C. Walker

Summary: Despite progress in the development of anti-seizure medications (ASMs), one third of people with epilepsy have drug-resistant epilepsy (DRE). The working definition of DRE, proposed by the International League Against Epilepsy (ILAE) in 2010, helped identify individuals who might benefit from presurgical evaluation early on. There is a need to revisit the current definition of DRE in order to improve research, develop new treatments, and identify drug resistance earlier.

EPILEPSIA (2023)

Article Clinical Neurology

Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy

Nicola Specchio, Rima Nabbout, Eleonora Aronica, Stephane Auvin, Arianna Benvenuto, Luca de Palma, Martha Feucht, Floor Jansen, Katarzyna Kotulska, Harvey Sarnat, Lieven Lagae, Sergiusz Jozwiak, Paolo Curatolo

Summary: Children with tuberous sclerosis complex (TSC) often experience drug-resistant epilepsy, and significant progress has been made in understanding the mechanisms and management of TSC-associated epilepsy. Pre-symptomatic treatment with vigabatrin can delay seizure onset, while mTOR inhibition with everolimus and cannabidiol provide additional therapeutic options. Epilepsy surgery has shown to greatly improve seizure outcomes. Early identification of risk factors and genetic diagnosis, as well as the use of biomarkers, can contribute to the development of pre-symptomatic and disease-modifying strategies.

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2023)

Article Clinical Neurology

Uncommon use of intermittent glucose administration for infrequent non-epileptic paroxysmal events in GLUT1-DS

Soufiane Mortaji, Blandine Dozieres-Puyravel, Katia Geraldes, Celine Perrot, Virginie Quemener, Stephane Auvin

Summary: This article reports two cases of patients who were not following any particular diet and experienced infrequent paroxysmal non-epileptic events. Intermittent glucose intake before physical activity and at the onset of symptoms consistently improved the symptoms. The observations suggest the possibility of developing a new treatment strategy involving sustained increase in blood glucose. However, this strategy should currently be limited to a small group of GLUT1-DS patients not on a ketogenic diet.

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2023)

Meeting Abstract Clinical Neurology

Fenfluramine Treatment Is Associated With Improvement in Everyday Executive Function in Adults With Lennox-Gastaut Syndrome: Post-Hoc Analysis of Dose Effects From a Phase 3 Trial Rationale

Kim Bishop, Peter Isquith, Kelly Knupp, Joseph Sullivan, Rima Nabbout, Antonio Gil-Nagel, Ingrid Scheffer, Stephane Auvin, J. Helen Cross, Renzo Guerrini, Robert Roth, Gerard Gioia, Amelie Lothe, Shikha Polega

NEUROLOGY (2023)

No Data Available